1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation

 
• By Malcolm Spicer

Co-founder and CEO Michael Hufford says HRT hopes to distribute first commercial supply in early 2024. Firm is engaging additional funding partners to help make its affordable opioid overdose treatment more accessible.

RiVive nasal spray is second OTC naloxone formulation approved in US. • Source: Harm Reduction Therapeutics

Approval in the US of the second OTC product in a drug category typically doesn’t merit mention by the Food and Drug Administration commissioner.

Making opioid overdose treatment naloxone available OTC, however, isn’t a typical approval by the FDA.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By David Ridley

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By Tom Gallen

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By David Ridley

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By David Ridley

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.

More from Health

Reducing ‘Complexity Across The Organization’ Tops Kenvue Interim CEO’s Priorities

 
• By Malcolm Spicer

Three weeks into his appointment as interim CEO, Kirk Perry sets priorities including “reduce organizational complexity,” “reinforce a consumer-centric mindset” and “refocus on household penetration.”

Softness In US And China Holds Back Bayer Consumer Health

 
• By Tom Gallen

Like its peers, Bayer Consumer Health has struggled in the challenging US market in the first half of 2025 and says it doesn't expect conditions to change this year.

Repeat Buyers Passing 50% Key For Opill Sales Leading Perrigo’s Women’s Health Growth

 
• By Malcolm Spicer

“We continue to grow the brand. It was slower than initially anticipated or forecasted in basis, but I'm pleased with how it's developing,” says CEO Patrick Lockwood-Taylor of Opill performance.